New research suggests that people who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional diet and exercise regimens.
Findings released in a leading health publication points out that while overweight people can lose substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using these medications need to be cognizant of the potential of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass in about a year and a half.
Comparing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, compared the results of these new drugs with older methods.
The team emphasize that individuals who lose weight through lifestyle changes alone generally experience a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts believe the mode of action of the jabs explains the heightened weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating much more probable."
An Ongoing Issue?
The NHS suggest the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, given the high risk of relapse, the therapy should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic nature of obesity," akin to managing conditions like hypertension.
User Testimonies
People who have discontinued the medication explain a intense return of hunger.
"I experienced a switch that goes on and you become starving," described one woman.
This challenge is compounded if patients have not adopted lasting dietary or behavioural changes during treatment.
Widespread Interest
Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is higher among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing lifestyle management.
